JP2009521956A5 - - Google Patents

Info

Publication number

JP2009521956A5

JP2009521956A5 JP2008549643A JP2008549643A JP2009521956A5 JP 2009521956 A5 JP2009521956 A5 JP 2009521956A5 JP 2008549643 A JP2008549643 A JP 2008549643A JP 2008549643 A JP2008549643 A JP 2008549643A JP 2009521956 A5 JP2009521956 A5 JP 2009521956A5

Authority

JP

Japan

Prior art keywords

hvr

antibody

ephb4

seq

composition

Prior art date

2007-01-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004027 cell Anatomy 0.000 claims 13
• 238000000034 method Methods 0.000 claims 12
• 238000006467 substitution reaction Methods 0.000 claims 9
• 239000004037 angiogenesis inhibitor Substances 0.000 claims 8
• 201000010099 disease Diseases 0.000 claims 8
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 6
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 6
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 6
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 6
• 239000013598 vector Substances 0.000 claims 6
• 206010028980 Neoplasm Diseases 0.000 claims 4
• 230000033115 angiogenesis Effects 0.000 claims 4
• 239000005557 antagonist Substances 0.000 claims 4
• 239000003814 drug Substances 0.000 claims 4
• 230000002401 inhibitory effect Effects 0.000 claims 3
• 238000004519 manufacturing process Methods 0.000 claims 3
• 102000040430 polynucleotide Human genes 0.000 claims 3
• 108091033319 polynucleotide Proteins 0.000 claims 3
• 239000002157 polynucleotide Substances 0.000 claims 3
• 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims 2
• 239000002246 antineoplastic agent Substances 0.000 claims 2
• 229960000397 bevacizumab Drugs 0.000 claims 2
• 239000012472 biological sample Substances 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 229940127089 cytotoxic agent Drugs 0.000 claims 2
• 210000003527 eukaryotic cell Anatomy 0.000 claims 2
• 229940127121 immunoconjugate Drugs 0.000 claims 2
• 238000012986 modification Methods 0.000 claims 2
• 230000004048 modification Effects 0.000 claims 2
• 210000001236 prokaryotic cell Anatomy 0.000 claims 2
• 230000002062 proliferating effect Effects 0.000 claims 2
• 238000011321 prophylaxis Methods 0.000 claims 2
• 230000001225 therapeutic effect Effects 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 102220582564 4-hydroxy-2-oxoglutarate aldolase, mitochondrial_N78A_mutation Human genes 0.000 claims 1
• 102220492945 Nuclear RNA export factor 1_R71A_mutation Human genes 0.000 claims 1
• 102220506801 Vitelline membrane outer layer protein 1 homolog_N73T_mutation Human genes 0.000 claims 1
• 238000011260 co-administration Methods 0.000 claims 1
• 238000012217 deletion Methods 0.000 claims 1
• 230000037430 deletion Effects 0.000 claims 1
• 238000001514 detection method Methods 0.000 claims 1
• 239000013604 expression vector Substances 0.000 claims 1
• 238000003780 insertion Methods 0.000 claims 1
• 230000037431 insertion Effects 0.000 claims 1
• OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 claims 1
• 210000004962 mammalian cell Anatomy 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 238000011282 treatment Methods 0.000 claims 1